Industry Report: ``Major Developments in the Treatment of HIV/AIDS'' Features Aethlon Medical

SAN DIEGO, Apr 11, 2005 - Aethlon Medical, Inc. (OTCBB: AEMD) announced today that the Company is featured in an April 2005 report entitled: "Major Developments in the Treatment of HIV/AIDS". The 51-page report, published by Griffin Securities, Inc., provides a comprehensive review of the major developments in the treatment of HIV/AIDS, including a description of the Aethlon Hemopurifier(TM) as a potential new treatment for drug resistant patients and as a conjunctive therapy to extend the effectiveness of current drug regimens. Other Companies that are featured in the report include: Abbott Pharmaceuticals, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Merck & Co, Pfizer, Roche Pharmaceuticals, and Trimeris, Inc. To request a copy of the report, Contact Anne Hoversten at Aethlon Medical, Inc. at 858-459-7800 x300, or Griffin Securities directly at 212-509-9500.

About Aethlon Medical

Aethlon Medical is pioneering the development of viral filtration devices to treat HIV/AIDS, Hepatitis-C (HCV), and pathogens that are mass casualty biological warfare candidates. Each treatment application employs the use of a proprietary technology known as the Hemopurifier(TM), which is designed to rapidly reduce the presence of infectious disease and toxins in the body. The Hemopurifier converges the established scientific principals of affinity chromatography and hemodialysis as a means to augment the immune response of clearing viruses and toxins from the blood before cell and organ infection can occur. More information on Aethlon Medical and the Hemopurifier technology is available at www.aethlonmedical.com.

About Griffin Securities

Griffin Securities, Inc., is a New York City based Investment Banking firm providing Corporate Finance, Merger & Acquisitions, Asset Management, Brokerage and Research services for Institutional, Corporate and Private Clients. The firm is a member of the National Association of Securities Dealers (NASD) (Broker ID 43229) and the Securities Investor Protection Corporation (SIPC). The firm is a subsidiary of Griffin Group plc), a financial services firm based in the U.K. whose other subsidiary, Griffin Securities UK Ltd., is authorized and regulated by the Financial Services Authority (FSA). The group provides financial advisory services to emerging growth companies, institutions, and high net worth individuals.

Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company's ability to manufacture its products and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.

SOURCE: Aethlon Medical, Inc.

Aethlon Medical, Inc. is a featured Company on HomelandDefenseStocks.com

For full details, click here: http://www.homelanddefensestocks.com/Companies/AethlonMedical/Default.asp

Contact:
Aethlon Medical, Inc.
Anne Hoversten (Investor Relations), 858-459-7800 x300
anne@aethlonmedical.com